Coya Therapeutics, Inc. (COYA) intrinsic value & 10-year financials
Coya Therapeutics, Inc. (COYA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 15.1% a year to $7.9M, with an average return on invested capital of 35.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.25
- Market cap
- $71.1M
- Revenue (FY2025)
- $7.9M
- Revenue growth (6-yr CAGR)
- 15.1%
- ROIC (10-yr avg)
- 35.0%
- Free cash flow (FY2025)
- —
COYA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.9M | -$21.2M | -$1.27 | — | -283.9% | -54.6% |
| FY2024 | $3.6M | -$14.9M | -$0.98 | — | -485.4% | -43.8% |
| FY2023 | $6.0M | -$8.0M | -$0.79 | — | -131.7% | -58.0% |
| FY2022 | $0 | -$12.2M | -$1.18 | — | — | 413.2% |
| FY2021 | — | -$4.9M | -$0.47 | — | — | -81.9% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Coya Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Coya Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -46.8% ROIC.
Coya Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Coya Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-42.18 per share.